Recent study also found that thalidomide played an important role in treating refractory inflammatory bowel disease (IBD).[5–7] Thalidomide as an immunosuppressive agent, inhibited mononuclear cell factor to play the role of immunosuppression and stimulated T lymphocyte activation to activate immunoreaction, its antiinflammatory mechanism is to inhibit the release of tumor necrosis factor-α (TNF-α) by inhibiting synthesis of TNF-α, which led from promoting degradation of TNF-α mRNA.[16–18] Waters et al[19] first reported that thalidomide might effectively treat refractory UC in 1979. The gene discussed is TNF; the disease is inflammatory bowel disease.